Form 4: Sangamo Therapeutics Executive Reports Stock Transactions Following RSU Vesting

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, reports the acquisition and disposition of company stock related to RSU vesting and tax withholding.

Summary

• Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• The reported transactions include the acquisition of 49,726 shares of common stock on February 25, 2025, related to the vesting of a restricted stock unit (RSU) grant.
• Davis also disposed of 705 shares on February 24, 2025, and 507 shares on February 25, 2025, to cover mandatory tax withholding obligations associated with RSU vesting.
• These dispositions were not discretionary trades but were required under the terms of the company's Amended and Restated 2018 Equity Incentive Plan.
• Following these transactions, Davis beneficially owns 216,084 shares of Sangamo Therapeutics common stock.
• Davis also acquired 99,454 stock options on February 25, 2025, exercisable beginning February 24, 2035.

Sentiment

Score: 6

Explanation: The document reflects routine executive compensation activity. It is neither overwhelmingly positive nor negative, but rather a standard disclosure.

Positives

• The vesting of RSUs indicates that Davis is meeting the requirements for continued service with the company.
• The acquisition of stock options suggests a long-term commitment to the company's success.

Future Outlook

The reported RSU grants will continue to vest in quarterly installments through February 24, 2026, and January 22, 2026, subject to the Reporting Person's continued service.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. The vesting of RSUs is a common practice in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• RSU grants and stock option awards are standard compensation practices for executives in publicly traded biotechnology companies.
• Companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize similar equity-based compensation plans to align executive interests with shareholder value.
• The vesting schedules and terms of these grants are generally comparable across the industry, with vesting contingent on continued service and performance milestones.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they reflect the ongoing dilution associated with equity compensation plans.
• Employees may view the RSU vesting as a positive sign of the company's commitment to its employees.

Key Dates